Laura F. Newell

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 958 citations · Full text

Mixed-phenotype Acute Leukemia, Pharmacotherapy, Metronomic Chemotherapy +16

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia

Alyssa Carey, David K. Edwards, Christopher A. Eide et al. · Cell Reports · 2017 · 257 citations · Full text

BMPs signal alternately through a SMAD or FRAP–STAT pathway to regulate fate choice in CNS stem cells

Prithi Rajan, David M. Panchision, Laura F. Newell et al. · The Journal of Cell Biology · 2003 · 204 citations · Full text

Bmps Signal, Stem Cell Biology, Cell Specialization +18

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell et al. · The Lancet Haematology · 2021 · 200 citations

Hematological Malignancy, Oncology, Cpx-351 Versus 7+3 +11

Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2016 · 164 citations

Secondary Aml, Prognosis, Pharmacotherapy +17